Kura Oncology, Inc. (KURA) Stock Profile — Insider Trades & Financials

Revenue$17.3M

Net Income-$81.0M

EPS$-3.18

Market Cap$776.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Troy Wilson

CEO & Executive Director

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The companyâs first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Founded: 2014
Employees: 260
Headquarters: San Diego, California, United States

⚡

Core Efficiency

ROE?

-46.52%

ROA?

-10.97%

D/E Ratio?

3.24

Op. Margin?

-497.62%

📊

Profitability Ratios

Net Margin?

-467.23%

Loading company sections...

Kura Oncology, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness